Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 5/20 | 0.38 |
| ▸ | TNKS | O95271 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.38 |
| ▸ | TYMS | P04818 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25080175 | 0.82 | PARP1 (0.40) | PARP1TNKSTNKS2ADORA3CYP1A2 | |
| SCHEMBL18703618 | 0.79 | SPR (0.38) | SPRPARP1TNKSTNKS2 | |
| SCHEMBL18711958 | 0.79 | SPR (0.39) | SPRPARP1TNKSTNKS2ADORA3 | |
| SCHEMBL18701526 | 0.79 | TNKS (0.39) | SPRPARP1TNKSTNKS2 | |
| SCHEMBL18703619 | 0.79 | SPR (0.37) | SPRPARP1TNKSTNKS2HPGD | |
| SCHEMBL18703620 | 0.78 | SPR (0.37) | SPRPARP1TNKSTNKS2 | |
| SCHEMBL16707618 | 0.71 | TNKS (0.51) | SPRPARP1TNKSTNKS2 | |
| SCHEMBL17241119 | 0.68 | SPR (0.37) | SPRPARP1TNKSHPGD | |
| SCHEMBL15527637 | 0.68 | TNKS (0.47) | SPRPARP1TNKSTNKS2HPGD | |
| SCHEMBL12102064 | 0.68 | TNKS2 (0.36) | SPRPARP1TNKSTNKS2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | SPR 1/4885PARP1 2611/4885TNKS 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.